Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 2.20% is 25% above its 2-year average of 1.77%, around the middle of its 2-year range (0.47%–4.16%).
As of the fiscal period ended Tuesday, June 30, 2026. 15.24% below its 12-month average of 2.60%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 2.20%.
DEBT TO ASSETS RATIO
2.20%
DEBT TO ASSETS RATIO AVG TTM
2.60%
DEBT TO ASSETS RATIO AVG 3Y
N/A
DEBT TO ASSETS RATIO AVG 5Y
N/A
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-15.24%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+2346.23%
vs the sector median at left
Rapport Therapeutics, Inc. Common Stock
Market Cap
$1.49B
Debt to Assets Ratio
2.20%
TTM Avg
2.60%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.48B
Debt to Assets Ratio
0.53%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.50B
Debt to Assets Ratio
0.25%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.46B
Debt to Assets Ratio
0.11%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. Common Stock (RAPP) | $1.49B | 2.20% | 2.60% | N/A | N/A |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 0.53% | N/A | N/A | N/A |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 0.25% | N/A | N/A | N/A |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 0.36% | N/A | N/A | N/A |
| GH Research PLC (GHRS)vs › | $1.48B | 0.00% | N/A | N/A | N/A |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | 0.11% | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 0.02% | N/A | N/A | N/A |
| Innoviva, Inc. (INVA)vs › | $1.54B | 0.16% | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | 0.21% | N/A | N/A | N/A |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | 0.84% | N/A | N/A | N/A |
Debt/Assets
2.2%
Debt/Equity
0.02
Current Ratio
15.72
Interest Coverage
N/A
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 2.20% |
| 2026-03-31 | 2.17% |
| 2025-12-31 | 2.24% |
| 2025-09-30 | 2.22% |
| 2025-06-30 | 4.16% |
| 2025-03-31 | 2.60% |
| 2024-12-31 | 0.47% |
| 2024-09-30 | 0.50% |
| 2024-06-30 | 0.53% |
| 2024-03-31 | 0.96% |
| 2023-12-31 | 1.38% |
